Latest news with #BKV
Business Wire
21-07-2025
- Business
- Business Wire
BKV Corp. Expands Strategic Partnership with Leading Midstream Operator to Advance Carbon Capture and Sequestration Development
DENVER--(BUSINESS WIRE)--BKV Corporation ('BKV' or the 'Company') (NYSE: BKV) today announced the execution of an agreement with a leading diversified midstream energy company to develop a new carbon capture and sequestration ('CCS') project at a currently operating natural gas processing plant in East Texas. The agreement expands on a previously announced agreement between the companies to develop a separate CCS project at a location in South Texas. The new CCS project will be constructed on the same site as an existing East Texas natural gas processing plant and is expected to be operational in early 2027. Under the terms of the agreement, BKV forecasts approximately 70,000 metric tons per year of carbon dioxide ('CO 2 ') waste stream could be captured at the plant, which would then be delivered to BKV to be compressed, transported and permanently sequestered via BKV's co-located Class II injection well. The co-located Class II injection well eliminates the need to invest in a high-pressure pipeline. The East Texas CCS project will be owned by BKV, but may be transferred to the Company's recently announced CCS joint venture ('JV') with Copenhagen Infrastructure Partners. 'Deepening our relationships with key partners demonstrates their confidence in our technical and operating expertise in developing and scaling carbon capture, utilization and sequestration projects,' said Chris Kalnin, Chief Executive Officer of BKV. 'As demand for low-carbon energy solutions continues to grow, we are pleased to expand our existing business relationship with one of the largest midstream providers in the United States.' The new CCS project adds to BKV's carbon capture, utilization and sequestration ('CCUS') portfolio, which includes the operational CCS project at the Company's Barnett Zero site in north Texas, the aforementioned South Texas project and the Cotton Cove CCS project, which has reached FID and remains on track to begin initial sequestration operations in the first half of 2027. About BKV Corporation Headquartered in Denver, Colorado, BKV Corporation is a forward-thinking, growth-driven energy company focused on creating value for its stockholders. BKV's core business is to produce natural gas from its owned and operated upstream assets. BKV's overall business is organized into four business lines: natural gas production; natural gas gathering, processing and transportation; power generation; and carbon capture, utilization and sequestration. BKV (and its predecessor entity) was founded in 2015, and BKV and its employees are committed to building a different kind of energy company. BKV is one of the top 20 gas-weighted natural gas producers in the United States and the largest natural gas producer by gross operated volume in the Barnett Shale. BKV Corporation is the parent company for the BKV family of companies. For more information, visit the BKV website at Forward-Looking Statements The information in this press release includes 'forward-looking statements' within the meaning of the federal securities laws. Forward-looking statements, which are not historical facts, include statements regarding BKV's strategy, future operations, prospects, plans and objectives of management, and often contain words such as 'expect,' 'project,' 'estimate,' 'believe,' 'anticipate,' 'intend,' 'budget,' 'plan,' 'seek,' 'envision,' 'forecast,' 'target,' 'predict,' 'may,' 'should,' 'would,' 'could,' 'will,' the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including but not limited to assumptions, risks and uncertainties regarding our ability to successfully fund, pursue and develop our CCUS business; the expected increase in demand for power and our ability to serve that demand from our power business; and our ability to develop, market and sell our carbon sequestered gas product. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements discussed in BKV's filings with the United States Securities and Exchange Commission (the 'SEC'), including the 'Risk Factors' section of BKV's Annual Report on Form 10-K dated March 31, 2025. BKV undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. SOURCE: BKV Corporation
Business Wire
12-06-2025
- Health
- Business Wire
SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients
PARIS--(BUSINESS WIRE)-- SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABK led by Pr. Samira FAFI-KREMER, Director of the Institut de Virologie de Strasbourg and Pr. Pascal POIGNARD, Head of the "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble. This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients. Since the option agreement signed in 2024, SpikImm has already made progress in its preclinical work, and has successfully completed the development of the cell line for GMP manufacturing. The aim is to carry out the first in human studies by 2026. BK virus (BKV) infects most individuals early in life and typically remains latent without causing disease. However, under immunosuppressive treatment, in particular in transplant patients, BKV can reactivate and replicate in the urinary tract, leading to potentially serious complications. In kidney transplant recipients; BKV reactivation may result in graft loss and increase the risk of bladder cancer. In addition, BKV is responsible for severe hemorrhagic cystitis in bone marrow graft recipients. No BKV-specific antiviral therapies or vaccines are currently available. Therefore, there is an urgent medical need for the development of novel anti-BKV prophylactic treatments. Thanks to the work of Pr. FAFI-KREMER, Head of renowned Institut de Virologie of Strasbourg (U1109 University of Strasbourg / Inserm, Strasbourg University Hospitals) and her team, the key role of anti-BKV neutralizing antibodies for protection against BKV infection and associated diseases was uncovered. Building upon these insights, Pr. FAFI-KREMER and Pr. POIGNARD joined forces to develop anti-BKV neutralizing monoclonal antibodies under the HuMABK project, funded by ANR and SATT Conectus. The expertise in antibody discovery of Pr. POIGNARD and collaborators of the Institut de Biologie Structurale (CEA/CNRS / University of Grenoble Alpes / UMR 5075) enabled the successful isolation of broad and potent anti-BKV neutralizing human monoclonal antibodies. These monoclonal antibodies represent promising candidates for future clinical development as potential best-in-class options. SpikImm and SATT Conectus today announced the signature of a worldwide exclusive licensing agreement for the anti-BKV monoclonal antibodies. These antibodies are engineered to potentially provide effective, long-lasting protection against the serious complications associated with BKV, offering a prophylactic solution for transplant recipients. With its partners Institut Pasteur and LFB, SpikImm has already demonstrated its expertise in rapidly bringing from discovery to clinical trials two anti-SARS COV2 monoclonal antibodies within twelve months, creating a unique platform for the accelerated discovery and development of monoclonal antibodies to the benefit of patients. SpikImm is focused on the accelerated development of long-acting monoclonal antibodies to protect immunocompromised patients from several viral infections, including SARS-CoV-2 and BKV. Pr. FAFI-KREMER, PharmD, PhD, University Professor-Hospital Practitioner, Head of Institut de Virologie de Strasbourg (U1109 University of Strasbourg / Inserm, Strasbourg University Hospitals) and Pr. POIGNARD, M.D., Ph.D, University Professor-Hospital Practitioner (University of Grenoble Alpes - CHU Grenoble-Alpes), Head of "Antibodies and Infectious Diseases" research team at the Institut de Biologie Structurale of Grenoble (CEA-CNRS-UGA Mixed Research Unit 5075) comment: "Reactivation of the BK virus in patients receiving kidney transplant, bone marrow or stem cell grafts has potential serious consequences and represents a growing medical challenge. The HuMABK monoclonal antibodies discovered by Grenoble's Institut de Biologie Structurale in collaboration with Strasbourg's Institut de Virologie are remarkably effective in neutralizing this virus and represent a promising antiviral strategy. We are convinced that the collaboration with SpikImm will ensure a rapid clinical development. Specifically, we anticipate that the monoclonal antibodies will significantly enhance patient care, notably by preserving kidney transplants, and promoting favorable outcomes in bone marrow recipients. ' James PHILLIPS, MD, CEO of SpikImm, comments: "We are delighted to sign this agreement for these highly promising monoclonal antibodies against the BK virus. SpikImm will be able to draw on the exceptional quality of the research team, as well as the strong support of SATT Conectus, to advance this project and bring new hope to the vulnerable immunocompromised patients.' Philippe POULETTY, MD, chairman of SpikImm comments " SpikImm's mission is to protect immunocompromised patients from severe viral diseases. These potent anti-BKV monoclonal antibodies will reinforce SpikImm's pipeline to offer broad protection against several severe infections. SpikImm embodies Truffle Capital approach: to actively create and grow companies with outstanding science to address major unmet needs.' Emmanuel POTEAUX, Chairman and CEO of SATT Conectus, highlights: " The signing of this technology licence marks an outstanding scientific collaboration between two leading researchers working at the heart of two regions of academic excellence, Alsace and Grenoble. The combined financial investment from the ANR and SATT Conectus made it possible to obtain and validate robust preclinical results, paving the way for clinical development. We are delighted that SpikImm is taking over to continue the development of this major health innovation for patients.' The HuMABK project is supported by: About SpikImm SpikImm is a French clinical-stage biotech founded by Truffle Capital in collaboration with Institut Pasteur in 2021 to develop human monoclonal antibodies for the prevention of severe infectious diseases affecting immunocompromised patients. SpikImm's lead candidates SPK001 and SPK002, have been originally developed in the laboratory of Humoral Immunology (Institut Pasteur & Inserm U1222) headed by Dr Hugo MOUQUET, as long-acting monoclonal antibodies for the prevention of COVID-19 in immunocompromised patients. SpikImm is currently expanding its portfolio of monoclonal antibodies against severe viral infections, through collaborations with prestigious academic research teams, starting with BKV infection. More information: About Truffle Capital Founded in 2001, Truffle Capital is an independent European Venture Capital firm specializing in Life Sciences (MedTech and BioTech) and disruptive technologies in the I.T. sector (FinTech and InsurTech). Truffle Capital's mission is to support the creation and development of young innovative companies capable of becoming tomorrow's leaders. Managed by Dr. Philippe Pouletty and Bernard-Louis Roques, co-founders and CEOs, Truffle Capital has €500 million in assets under management. It has raised more than €1.2 billion since its creation and has supported more than 70 companies in the digital technology and life sciences sectors. More information: — Twitter: @trufflecapital About SATT Conectus SATT* Conectus is the main entry point for business partners and companies to access all the innovations and capabilities from public research in Alsace, one of the top ranked territories for the excellence of research in France. Thanks to its investment fund, SATT CONECTUS offers advanced, applicative technologies whose proofs of concept have been established, and ready to industrialize. Therefore investors will have access to groundbreaking startups built around those breakthrough yet matured technologies. Another type of collaboration allows companies to co-develop high potential innovative projects with public research, in order to tailor them to their specific needs. * technology transfer acceleration organization More information: About the Institut de Virologie de Strasbourg The Institut de Virologie de Strasbourg, headed by Pr. FAFI KREMER is affiliated with the Faculty of Medicine of the University of Strasbourg, the Strasbourg University Hospitals and the Inserm Unit U1109, LabEx TRANSPLANTEX. For more than 10 years, his research has focused on the study of virus-host interaction in the pathogenesis of polyomaviruses (BK virus)-associated diseases in immunocompromised individuals, particularly transplant patients. The central aim is to ultimately identify accurate and personalized biomarkers and to develop urgently needed, preventive and therapeutic antiviral strategies. About the Institut de Biologie Structurale (IBS) The IBS, a mixed research unit CEA-CNRS-Université Grenoble Alpes (UMR 5075), hosts the "Antibodies and Infectious Diseases" research team headed by Pr. POIGNARD, specialized in the study of humoral responses to viral, bacterial and parasitic infections. After playing a key role in the discovery of broadly neutralizing antibodies against HIV, P Poignard has extended his interest to other viruses, such as the BK virus, but also to bacteria and parasites. In particular, his team focuses on the development of innovative strategies for the discovery of human monoclonal antibodies to develop new therapeutic approaches and help vaccine design.
Yahoo
12-05-2025
- Business
- Yahoo
BKV Corp (BKV) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Challenges
Revenue: Not explicitly mentioned in the transcript. Net Loss: $79 million or a loss of $0.93 per diluted share. Adjusted Net Income: $35 million or $0.41 per diluted share. Combined Adjusted EBITDAX: Just over $100 million, including $90 million from upstream and $10 million from power. Power JV Adjusted EBITDA: $20 million, with BKV's 50% share being $10 million. Development CapEx: $48 million, 26% below the midpoint of the guided range. Total CapEx: $58 million, significantly below the low end of the first quarter guidance range of $75 million. Net Production: 761 million cubic feet equivalent per day. Cash and Cash Equivalents: Approximately $15 million at the end of the first quarter. Net Leverage Ratio: Less than 0.7 times net debt to adjusted EBITDAX. Adjusted Free Cash Flow: $6 million, or $22 million excluding premiums paid. Hedging Position: 58% of natural gas hedged at $3.44 per MMBTU for 2025. Warning! GuruFocus has detected 4 Warning Signs with BKV. Release Date: May 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. BKV Corp (NYSE:BKV) is positioned to grow rapidly in multiple economic scenarios, leveraging megatrends in energy. The company is one of the largest natural gas producers in Texas, with robust domestic and global demand projections. BKV's carbon capture business is accelerating, supported by strong bipartisan backing for the 45Q tax credit. The company's power joint ventures in Texas are well-positioned to capitalize on growing power demand, particularly from data centers. BKV's four business linesupstream, midstream, carbon capture, and power generationcreate premium margins and differentiated products. The macroeconomic landscape presents challenges such as persistent inflation and potential tariff impacts. Despite strong performance, BKV reported a net loss of $79 million in the first quarter. There are concerns about the resilience of the 45Q tax credit, although BKV remains confident in its robustness. The company faces potential supply chain disruptions, although it projects minimal impact. BKV's CCS projects require significant capital investment, and the pace and scale of these investments may shift. Q: With the recent JV with CIP and Comstock projects, do you think the momentum behind CCS projects is picking up, especially for gas processing projects? A: Christopher Kalnin, CEO: The momentum for carbon capture, particularly in natural gas processing, is strong. The 45Q tax credit is robust, with bipartisan support, enhancing U.S. energy competitiveness. BKV is leading in carbon capture, crucial for decarbonizing power for data centers. Eric Jacobsen, President of Upstream, added that the momentum around natural gas processing plants remains strong, with robust project economics and BKV establishing itself as a leader in this space. Q: Why weren't the Cotton Cove and Comstock projects included in the JV? A: Eric Jacobsen, President of Upstream: The exclusion was due to timing criteria. The first two projects are in the JV, with more to come in the FID and pre-FID phases. Q: Can you explain the unchanged CapEx for CCUS despite the new JV? A: Eric Jacobsen, President of Upstream: The JV with CIP allows us to optimize capital spend in CCS and diversify across other sectors. While the aggregate amount remains robust, near-term timing may shift. We remain committed to delivering on FID projects and achieving a 1 million ton per year CO2 injection rate by 2027. Q: What is your inclination to grow production given the current strip pricing? A: Eric Jacobsen, President of Upstream: We maintain a disciplined capital investment framework based on commodity price ranges. With current strip prices, we are committed to 2-3% growth for 2025. We are monitoring macroeconomic conditions closely and have the opportunity set to invest further if conditions remain favorable. Q: Can you elaborate on the funding mechanism for the JV with CIP? A: David Tameron, CFO: While specific upfront capital details are confidential, the JV provides significant flexibility and a funding mechanism. Capital will be drawn down over 12 to 24 months as projects are deployed. Projects will be contributed to the JV based on board approval. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
10-05-2025
- Business
- Yahoo
BKV, CIP form JV with $500m investment to develop CCUS projects
BKV, in partnership with Copenhagen Infrastructure Partners (CIP), has established a carbon capture joint venture (JV) investment aimed at advancing carbon capture, utilisation and sequestration (CCUS) projects across the US. CIP, through its Energy Transition Fund I, will invest $500m for up to a 49% stake in the JV. The JV will capitalise on BKV's expertise as an early pioneer in CCUS projects, complemented by CIP's experience in developing low-carbon infrastructure. The collaboration is set to enhance BKV's existing portfolio of CCUS initiatives, with the Barnett Zero and Eagle Ford projects already integrated into the venture. BKV will maintain operational control of the JV's projects, holding a 51% interest. BKV's CCUS portfolio, which includes several projects at different stages of development, is expected to contribute further to the JV as they progress. BKV CEO Chris Kalnin said: 'This strategic partnership with CIP, a world-scale asset manager of low-carbon infrastructure projects, further strengthens the economics of BKV's CCUS business while enabling the acceleration of its growth. 'Together, we will expand our pipeline of carbon capture, utilisation and sequestration projects to help meet the increasing demand for low-carbon energy solutions. By combining BKV's technical and operating expertise in developing and scaling CCUS projects with CIP's expansive network, project portfolio and experience in infrastructure development, we are well positioned to grow our CCUS business. This partnership accelerates our efforts to expand into adjacent markets, industries and geographies.' The Barnett Zero Project in north Texas has already sequestered more than 200,000 tonnes of CO₂ equivalent since its inception in November 2023. The Eagle Ford Project in south Texas is projected to commence initial injection by the first half of 2026, pending all necessary permits and agreements. Jefferies led the financial advisory for the transaction, while BakerHostetler provided legal counsel to BKV. Earlier in the month, BKV also entered into a preliminary agreement with Comstock Resources to explore carbon capture initiatives, further solidifying BKV's commitment to CCUS solutions within the energy sector. "BKV, CIP form JV with $500m investment to develop CCUS projects" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
09-05-2025
- Business
- Washington Post
BKV: Q1 Earnings Snapshot
DENVER — DENVER — BKV Corp. (BKV) on Friday reported a loss of $78.7 million in its first quarter. The Denver-based company said it had a loss of 93 cents per share. Earnings, adjusted for one-time gains and costs, came to 41 cents per share. The natural gas producer posted revenue of $78.8 million in the period.
